Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

Back to signals Ask the Agent

CGENBullishEarningsShort Term

High materiality8/10

Compugen Reports Second Quarter 2026 Results

StockNews.AIAug 3, 7:00 AM EDT1 source

Trading thesisImportance 8/10

Bullish on COM701 timing; a positive 1Q2027 PFS readout could re-rate CGEN within 6–12 months.

AI summary

What happened and why it matters

Compugen reported Q2 2026 results, reaffirming progress across its immuno-oncology pipeline. The key catalyst is the MAIA-ovarian trial, with interim median progression-free survival data expected by 1Q2027, potentially signaling a pivotal inflection for COM701. Partnerships with AstraZeneca and Gilead advance rilvegostomig and GS-0321, while cash runway extends into 2029, supporting ongoing pipeline development.

Interim COM701 MAIA-ovarian PFS data by 1Q2027 acts as key catalyst.
AZN rilvegostomig OS readout at ASCO 2026 could validate pipeline.
GS-0321 Phase 1 progress with Gilead license adds near-term upside.
Cash runway extended into 2029 supports continued R&D investment.

Sentiment rationale

Key catalysts (COM701 interim PFS, OS readouts from rilvegostomig, and continued Phase 1 progress) could drive upside if data meet or exceed expectations. Positive data would directly affect pipeline valuation and potential registration paths, while cash runway supports ongoing execution; negative surprises could dampen fundamentals, but near-term catalysts are the primary driver.

Key facts

01
COM701 MAIA-ovarian interim PFS data expected by 1Q2027; trial on track.
02
ESMO Gynaecological Cancers poster reinforces COM701 rationale in platinum-sensitive ovarian cancer.
03
AZN rilvegostomig OS readout (16.8 months) highlighted; ongoing Phase 3 studies.
04
GS-0321 Phase 1 progress under Gilead license; Compugen remains cash-positioned into 2029.

Corporate Developments

Category: Corporate Developments. The release combines quarterly results with pipeline updates and partner data, creating near-term catalysts around COM701, rilvegostomig, and GS-0321 that can influence CGEN’s valuation as milestones approach.